Denibulin

Drug Profile

Denibulin

Alternative Names: Denibulin di-hydrochloride; Denibulin-hydrochloride; MN-029

Latest Information Update: 30 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Angiogene Pharmaceuticals
  • Developer MediciNova
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 13 Jan 2016 MediciNova receives patent allowance for denibulin in Europe
  • 16 Dec 2015 Denibulin is available for licensing in China (http://medicinova.com/)
  • 14 Dec 2015 MediciNova receives patent allowance for denibulin in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top